39 studies found for:    "Vatalanib"
Show Display Options
Rank Status Study
1 Completed PTK 787 and Gleevec in Patients With AML, AMM, and CML-BP
Conditions: Acute Myelogenous Leukemia;   Agnogenic Myeloid Metaplasia;   Chronic Myelogenous Leukemia
Interventions: Drug: Imatinib Mesylate (Gleevec);   Drug: PTK 787 (vatalanib)
2 Completed PTK787/ZK222584 in the Treatment of Metastatic Gastrointestinal Stromal Tumors Resistant to Imatinib
Condition: Sarcoma
Intervention: Drug: PTK787/ZK222584
3 Completed Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Previously Treated Metastatic Colorectal Cancer
Conditions: Colorectal Neoplasms;   Colonic Neoplasms;   Rectal Neoplasms
Intervention: Drug: Vatalanib
4 Completed Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Metastatic Colorectal Cancer.
Conditions: Colorectal Neoplasms;   Colonic Neoplasms;   Rectal Neoplasms
Intervention: Drug: Vatalanib
5 Completed
Has Results
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
Conditions: Leukemia;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Neoplasms
Intervention: Drug: vatalanib
6 Unknown  Trial of PTK787/ZK 222584 Plus Paclitaxel
Condition: Metastatic Non-hematologic Malignancies
Interventions: Drug: PTK787/ZK 222584;   Drug: paclitaxel
7 Completed PTK787/ZK222584 With Bevacizumab in Patients With Refractory and/or Advanced Malignancies
Conditions: Refractory Malignancy;   Advanced Malignancies
Intervention: Drug: PTK787/ZK222584 and Bevacizumab
8 Terminated PTK787 in Refractory or Relapsed Diffuse Large Cell Lymphoma
Condition: Lymphoma, Large-Cell, Diffuse
Intervention: Drug: PTK787
9 Completed Study of the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Effects of Vatalanib in Combination With Capecitabine in Patients With Advanced Cancer
Conditions: Tumors;   Neoplasm Metastasis
Intervention: Drug: PTK787/ZK 222584 (vatalanib)
10 Active, not recruiting Vatalanib in Treating Patients With Recurrent or Progressive Meningioma
Conditions: Brain and Central Nervous System Tumors;   Sarcoma
Intervention: Drug: vatalanib
11 Completed Phase I/II PTK787/ZK 222584 and Gemcitabine in Advanced Pancreatic Cancer
Condition: Pancreatic Cancer
Interventions: Drug: PTK787/ZK 222584;   Drug: Gemcitabine
12 Completed Imatinib Mesylate, Vatalanib, and Hydroxyurea in Treating Patients With Recurrent or Relapsed Malignant Glioma
Condition: Brain and Central Nervous System Tumors
Interventions: Drug: hydroxyurea;   Drug: imatinib mesylate;   Drug: vatalanib
13 Active, not recruiting Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors
Conditions: Gastrinoma;   Glucagonoma;   Insulinoma;   Metastatic Gastrointestinal Carcinoid Tumor;   Metastatic Pheochromocytoma;   Pancreatic Polypeptide Tumor;   Recurrent Gastrointestinal Carcinoid Tumor;   Recurrent Islet Cell Carcinoma;   Recurrent Melanoma;   Recurrent Neuroendocrine Carcinoma of the Skin;   Recurrent Non-small Cell Lung Cancer;   Recurrent Pheochromocytoma;   Recurrent Renal Cell Cancer;   Somatostatinoma;   Stage III Neuroendocrine Carcinoma of the Skin;   Stage IV Melanoma;   Stage IV Non-small Cell Lung Cancer;   Stage IV Renal Cell Cancer;   Thyroid Gland Medullary Carcinoma;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: everolimus;   Drug: vatalanib;   Other: pharmacological study;   Other: laboratory biomarker analysis;   Procedure: dynamic contrast-enhanced magnetic resonance imaging;   Procedure: ultrasound imaging
14 Completed Vatalanib and Everolimus in Treating Patients With Advanced Solid Tumors
Conditions: Kidney Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: RAD001 (everolimus);   Drug: PTK787 (vatalanib)
15 Completed Treatment of Von Hippel-Lindau (VHL)-Related Hemangioblastoma With PTK787/ZK 222584
Conditions: Von Hippel-Lindau Disease;   Central Nervous System Capillary Hemangioblastoma;   Retinal Capillary Hemangioblastoma
Intervention: Drug: PTK787/ZK 222584
16 Completed Safety and Efficacy Study of PTK787/ZK222584 to Treat Metastatic Neuroendocrine Tumors
Condition: Metastatic Neuroendocrine Tumors
Intervention: Drug: vatalanib
17 Completed PTK787/ZK 222584 in Combination With Temozolomide and Radiation in Patients With Glioblastoma Taking Enzyme-Inducing Anti-Epileptic Drugs
Condition: Glioblastoma
Interventions: Drug: PTK787/ZK 222584;   Drug: Temozolomide;   Procedure: Radiation Therapy
18 Completed Safety and Efficacy of Oral PTK787 in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (AMD)
Condition: Wet Age-Related Macular Degeneration
Interventions: Drug: PTK787;   Drug: Placebo
19 Terminated PTK and Letrozole in Post-menopausal Women With Advanced Breast Cancer
Condition: Breast Neoplasms
Interventions: Drug: PTK787/ZK222584;   Drug: Letrozole
20 Completed PTK787 in Patients With Advanced Metastatic Pancreatic Adenocarcinoma
Condition: Neoplasm
Intervention: Drug: PTK787/ZK222584

Previous Page Studies Shown (1-20) Next Page (21-39) Show next page of results
Indicates status has not been verified in more than two years